Remimazolam is a new type of ultra⁃short⁃acting benzodiazepine sedative，with the pharmacological properties of rapid onset，rapid recovery，relatively small effects on liver and kidney function and hemodynamics，and specific antagonistic drugs. Remimazolam has good clinical sedation effect，few adverse reactions，no accumu⁃lation for long application，can be safely applied in clinical sedation，and suitable for elderly and critically ill patients，or is expected to become the preferred sedative in clinical practice.